LAMY engages in developing a business tapping the eLearning market and the gaming market by teaching financial knowledge and resource management to children. The company is headquartered in St. Petersburg, Florida. The company went IPO on 2024-04-30. The firm is engaged in developing and manufacturing mammalian and plant-derived exosomes using proprietary technologies for nucleic acid loading and targeted delivery to tissues and cells. The platform enables the custom production of exosomes with genetic functionality, capable of selectively targeting specific cells to address diseases with unmet medical needs. The engineered exosomes have demonstrated the potential to target cancer stem cells, the primary drivers of recurrence and metastasis in various cancers, including glioblastoma and pancreatic cancer. Its proprietary manufacturing process utilizes plant-based materials to create exosomes used in various commercial applications, including dermatology and dentistry.
How did LMMY's recent EPS compare to expectations?
The most recent EPS for LAMY is $, expectations of $.
How did LAMY LMMY's revenue perform in the last quarter?
LAMY revenue for the last quarter is $
What is the revenue estimate for LAMY?
According to of Wall street analyst, the revenue estimate of LAMY range from $ to $
What's the earning quality score for LAMY?
LAMY has a earning quality score of B+/46.534374. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does LAMY report earnings?
LAMY next earnings report is expected in
What are LAMY's expected earnings?
LAMY expected earnings is $, according to wall-street analysts.